Literature DB >> 27264179

A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.

Kaitlyn M Gayvert1, Etienne Dardenne2, Cynthia Cheung2, Mary Regina Boland3, Tal Lorberbaum4, Jackline Wanjala5, Yu Chen5, Mark A Rubin6, Nicholas P Tatonetti3, David S Rickman7, Olivier Elemento8.   

Abstract

Mutations in transcription factor (TF) genes are frequently observed in tumors, often leading to aberrant transcriptional activity. Unfortunately, TFs are often considered undruggable due to the absence of targetable enzymatic activity. To address this problem, we developed CRAFTT, a computational drug-repositioning approach for targeting TF activity. CRAFTT combines ChIP-seq with drug-induced expression profiling to identify small molecules that can specifically perturb TF activity. Application to ENCODE ChIP-seq datasets revealed known drug-TF interactions, and a global drug-protein network analysis supported these predictions. Application of CRAFTT to ERG, a pro-invasive, frequently overexpressed oncogenic TF, predicted that dexamethasone would inhibit ERG activity. Dexamethasone significantly decreased cell invasion and migration in an ERG-dependent manner. Furthermore, analysis of electronic medical record data indicates a protective role for dexamethasone against prostate cancer. Altogether, our method provides a broadly applicable strategy for identifying drugs that specifically modulate TF activity.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27264179      PMCID: PMC4912004          DOI: 10.1016/j.celrep.2016.05.037

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  23 in total

Review 1.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 2.  Transcription factors: their potential as targets for an individualized therapeutic approach to cancer.

Authors:  C Mees; J Nemunaitis; N Senzer
Journal:  Cancer Gene Ther       Date:  2008-10-10       Impact factor: 5.987

3.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.

Authors:  David S Rickman; Ying-Bei Chen; Samprit Banerjee; Yihang Pan; Jindan Yu; Terry Vuong; Sven Perner; Christopher J Lafargue; Kirsten D Mertz; Sunita R Setlur; Kanishka Sircar; Arul M Chinnaiyan; Tarek A Bismar; Mark A Rubin; Francesca Demichelis
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Modulation of Hsf1 activity by novobiocin and geldanamycin.

Authors:  Renaud Conde; Zachery R Belak; Manoj Nair; Ruth F O'Carroll; Nick Ovsenek
Journal:  Biochem Cell Biol       Date:  2009-12       Impact factor: 3.626

6.  A comprehensive nuclear receptor network for breast cancer cells.

Authors:  Ralf Kittler; Jie Zhou; Sujun Hua; Lijia Ma; Yuwen Liu; Elisha Pendleton; Chao Cheng; Mark Gerstein; Kevin P White
Journal:  Cell Rep       Date:  2013-01-31       Impact factor: 9.423

7.  Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.

Authors:  D W-C Chen; V Saha; J-Z Liu; J-M Schwartz; M Krstic-Demonacos
Journal:  Oncogene       Date:  2012-08-06       Impact factor: 9.867

8.  A user's guide to the encyclopedia of DNA elements (ENCODE).

Authors: 
Journal:  PLoS Biol       Date:  2011-04-19       Impact factor: 8.029

9.  A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells.

Authors:  Li Xie; Claude Gazin; Sung Mi Park; Lihua J Zhu; Marie-anne Debily; Ellen L W Kittler; Maria L Zapp; David Lapointe; Stephane Gobeil; Ching-Man Virbasius; Michael R Green
Journal:  PLoS Genet       Date:  2012-12-20       Impact factor: 5.917

10.  PiHelper: an open source framework for drug-target and antibody-target data.

Authors:  Bülent Arman Aksoy; Jianjiong Gao; Gideon Dresdner; Weiqing Wang; Alex Root; Xiaohong Jing; Ethan Cerami; Chris Sander
Journal:  Bioinformatics       Date:  2013-06-12       Impact factor: 6.937

View more
  14 in total

1.  Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.

Authors:  Ok-Seon Kwon; Haeseung Lee; Hyeon-Joon Kong; Eun-Ji Kwon; Ji Eun Park; Wooin Lee; Seungmin Kang; Mirang Kim; Wankyu Kim; Hyuk-Jin Cha
Journal:  Oncogene       Date:  2020-05-09       Impact factor: 9.867

2.  Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes.

Authors:  Haloom Rafehi; Antony Kaspi; Mark Ziemann; Jun Okabe; Tom C Karagiannis; Assam El-Osta
Journal:  Epigenetics       Date:  2017       Impact factor: 4.528

3.  Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Authors:  Lian-Xiang Luo; Xing-Xing Fan; Ying Li; Xia Peng; Yin-Chun Ji; Wendy Wen-Luan Hsiao; Liang Liu; Elaine Lai-Han Leung; Xiao-Jun Yao
Journal:  Medchemcomm       Date:  2017-01-26       Impact factor: 3.597

4.  Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.

Authors:  Priyanka Dhingra; Alexander Martinez-Fundichely; Adeline Berger; Franklin W Huang; Andre Neil Forbes; Eric Minwei Liu; Deli Liu; Andrea Sboner; Pablo Tamayo; David S Rickman; Mark A Rubin; Ekta Khurana
Journal:  Genome Biol       Date:  2017-07-27       Impact factor: 13.583

Review 5.  The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis.

Authors:  Paul Laissue
Journal:  Mol Cancer       Date:  2019-01-08       Impact factor: 27.401

6.  Structural Basis of Inhibition of the Pioneer Transcription Factor NF-Y by Suramin.

Authors:  Valentina Nardone; Antonio Chaves-Sanjuan; Michela Lapi; Cristina Airoldi; Andrea Saponaro; Sebastiano Pasqualato; Diletta Dolfini; Carlo Camilloni; Andrea Bernardini; Nerina Gnesutta; Roberto Mantovani; Marco Nardini
Journal:  Cells       Date:  2020-10-29       Impact factor: 6.600

Review 7.  Drug Repositioning of the α1-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?

Authors:  Romane Florent; Laurent Poulain; Monique N'Diaye
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

8.  MD-Miner: a network-based approach for personalized drug repositioning.

Authors:  Haoyang Wu; Elise Miller; Denethi Wijegunawardana; Kelly Regan; Philip R O Payne; Fuhai Li
Journal:  BMC Syst Biol       Date:  2017-10-03

Review 9.  Drug Repositioning for Effective Prostate Cancer Treatment.

Authors:  Beste Turanli; Morten Grøtli; Jan Boren; Jens Nielsen; Mathias Uhlen; Kazim Y Arga; Adil Mardinoglu
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566

10.  Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells.

Authors:  Leanne Woods-Burnham; Christina K Cajigas-Du Ross; Arthur Love; Anamika Basu; Evelyn S Sanchez-Hernandez; Shannalee R Martinez; Greisha L Ortiz-Hernández; Laura Stiel; Alfonso M Durán; Colwick Wilson; Susanne Montgomery; Sourav Roy; Carlos A Casiano
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.